Taft Pharmaceutical Litigation & Life Sciences Litigation chair Steve Auten and attorney Jaimin Shah will be featured speakers at the 8th Annual Pharma IPR conference in Mumbai, India on March 6. Auten will present the session "Induced Infringement: Permissibility and Inevitability," which will cover evolution of induced infringement and inherency in an obviousness analysis. Shah will discuss “Competitive Generic Therapy Exclusivity.”
Auten is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 8,600 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
Shah focuses on patent litigation and counseling related to pharmaceuticals and biosimilars. Shah has represented world-class pharmaceutical companies in various phases of patent litigation, including generic versions of: Gilenya (fingolimod), Xeljanz (tofacitinib), Abilify (aripiprazole), Pazeo (olopatadine 0.7%), and the isosulfan blue dye. In addition to patent litigation, Jaimin counsels pharmaceutical companies on FDA-related matters. Prior to law school, he worked at a large India-based generic pharmaceuticals company. As a manager in the company’s Intellectual Property Cell, Shah gained first-hand knowledge in patent litigation strategy and the business realities that inform business and legal decisions.